An immunoassay for the quantification of phosphorylated α-synuclein at serine 129 in human cerebrospinal fluid
Open Access
- 15 October 2024
- journal article
- research article
- Published by Taylor & Francis in Bioanalysis
- Vol. 16 (21-22) , 1125-1139
Abstract
The link between alpha Synuclein (α-Syn) phosphorylation and Parkinson's disease pathogenesis has not been fully elucidated, in part due to analytical methods with finite specificity and sensitivity, resulting in conflicting data on pathophysiological levels of the protein.One factor hindering the assessment of the role of pSer129 α-Syn is the lack of a fit for purpose assay. Antibodies were assessed for quantification of pSer129 α-Syn, resulting in a sensitive and specific assay suitable for use in Parkinson's disease and control CSF, with no significant difference found between the two populations. Total α-Syn was measured using a commercial kit, demonstrating a positive correlation between total and pSer129 α-Syn.This adds to available methods for pSer129 α-Syn in support of α-synucleinopathy research.Keywords
This publication has 45 references indexed in Scilit:
- Status of Current Biofluid Biomarkers in Parkinson's DiseaseMovement Disorders Clinical Practice, 2023
- Sensitivity and specificity of phospho‐Ser129 α‐synuclein monoclonal antibodiesJournal of Comparative Neurology, 2018
- Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progressionMovement Disorders, 2016
- Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studiesActa Neuropathologica, 2015
- Alpha‐synuclein mRNA expression in oligodendrocytes in MSAGlia, 2014
- Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progressionAnnals of Neurology, 2010
- Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegenerationExperimental Neurology, 2008
- Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s diseaseBiochemical and Biophysical Research Communications, 2006
- Fit-for-Purpose Method Development and Validation for Successful Biomarker MeasurementPharmaceutical Research, 2006
- The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous systemNeuron, 1995